According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

Alyftrek’s approval could also extend Vertex’s market exclusivity in cystic fibrosis, as the drug’s main U.S. patent expires in 2039, two years after Trikafta’s. Vertex priced the therapy ...

CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...

Nordea Investment Management AB increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 19.4% during the fourth quarter, Holdings Channel reports. The ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta. Vertex has won two cystic fibrosis approvals from the FDA, but the agency ...

Last year Nicole Stringer went from very sick with cystic fibrosis to embracing an exciting, healthy lifestyle because of a new drug called Trikafta. “I was diagnosed with cystic fibrosis when I ...